Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor overall prognosis. Current standard of care involves surgical resection followed by adjuvant treatment with radiation (RT), temozolomide, and tumor treating fields (TTF) \[[@CR13]\]. Despite this aggressive treatment modality, median overall survival is approximately 15 months. Telomeres are terminal DNA elements found at eukaryotic chromosomal ends consisting of hexagonal repeats of (TTAGGG)~n~ which are essential for maintaining genomic stability \[[@CR1]\]. To maintain telomere length and circumvent the end-replication problem, most cancer cells express telomerase \[[@CR8]\]. Telomerase is composed of two subunits: a catalytic component with reverse-transcriptase activity encoded by the gene *TERT*, and an 11 base-pair RNA template encoded by the gene *TERC* \[[@CR11]\]. Mutations in the promoter region for *TERT* occur in approximately 60--80% of GBM, leading to increased telomerase activity and enabling replicative immortality \[[@CR10]\]. A defining feature of anaplastic astrocytomas and a small fraction of secondary GBM, is activation of a telomerase-independent alternative lengthening of telomeres (ALT) mechanism, driven by homologous recombination (HR) machinery \[[@CR7]\]. ALT tumors can readily be detected by assaying for the presence of extrachromosomal telomeric DNA C-Circles (CCs) via qPCR or ALT-associated telomere foci by FISH on pathological specimens \[[@CR6]\]. ALT+ high grade glioma (HGG) are enriched in tumors with loss of function mutations in *ATRX* (alpha-thalassemia/mental retardation X-linked) and less commonly, *SMARCAL1*. When these chromatin remodeling genes are inactivated, the resultant replication stress and aberrant HR at telomeres is hypothesized to lead to ALT \[[@CR2]\]. Mutations in both *ATRX* and *SMARCAL1* are mutually exclusive with *TERT* promoter mutations suggesting functional redundancy between these two mechanistic pathways \[[@CR3], [@CR4]\].

Here, we sought to identify and characterize ALT+ GBM by screening through a panel of 24 patient-derived GBM stem cell lines (GSCs). We tested for ALT using a novel qPCR method that measures both telomere content (TC), which is indicative of overall telomere length, and DNA C-Circles (CCs), which are specific and quantifiable markers for ALT activity \[[@CR9]\]. Telomerase expression was assessed by quantifying mRNA levels of *TERT* using whole transcriptome sequencing. ATRX protein expression was measured by immunoblotting.

Of the 24 GSCs that were tested, 2 were found to be ALT+ (8.3%), GS 5--22 and GS 8--18. These 2 cell lines have significantly elevated DNA CC content (*P* \< 0.001, t-test) and telomere content (*p* \< 0.001, t-test) relative to other GSCs (Fig. [1](#Fig1){ref-type="fig"}a and b). Furthermore, both GS 5--22 and GS 8--18 lack detectable full length ATRX protein upon immunoblot analysis (Fig. [1](#Fig1){ref-type="fig"}c). Whole transcriptome sequencing data (available for 22 of 24 GSCs) identified mRNA expression of *TERT* to be negligible in the two ALT+ GSCs, indicating absence of telomerase activity, whereas the remaining GSCs all had some quantifiable level of *TERT* expression (*p* = 0.0087, Mann-Whitney test) (Fig. [1](#Fig1){ref-type="fig"}d). Importantly, both GS 5--22 and GS 8--18 were derived from patients with secondary glioblastoma with concurrent *IDH* mutations. Also, p53 immunostaining was positive in both ALT+ GSCs (data not shown) corroborating p53 loss of function and mutant *IDH* along with ATRX loss as important in the development of ALT+ GBM. GS 5--22 and 8--18 display longer doubling times in vitro, 5 days and 8 days, respectively, relative to ATRX-intact *TERT*-positive GSCs which have a mean doubling time of \~ 3--4 days. We injected GS 522 cells intracranially into athymic mice to evaluate their ability to generate stable xenografts, and saw tumors form within 1 months' time (Fig. [1](#Fig1){ref-type="fig"}e).Fig. 1ALT+ GSCs were detected by quantifying telomere (**a**) and DNA C-Circle content (**b**) in a panel of 24 cell lines. Using a threshold cut-off value of 0.5 (dashed line) for telomere content and CCs, 2 ALT+ GSCs were identified, GS 8--18 and GS 5--22. Both GS 5--22 and GS 8--18 lack detectable ATRX protein (**c**). Additionally, these cell lines have negligible mRNA expression for *TERT* (**d**), indicating lack of telomerase activity. U-2 OS, a commercially available ALT+ osteosarcoma cell line which is *ATRX* mutant was used as a positive control for ALT and negative control for ATRX immunoblotting. Conversely, TS 603 and TS 543 which are known *ATRX* wild-type GSCs, were used as negative controls for ALT and positive controls for ATRX immunoblotting. GS 5--22 cells, stably expressing the luciferase reporter, were injected intracranially into nude mice and formed tumors within 4 weeks (**e**)

To date, only 2 ALT+ glioma cell lines have been documented (TG-20 and JHH-GBM14) \[[@CR5], [@CR12]\], however in these prior studies ALT was assayed for by immunofluorescent detection of telomere/PML body foci and lack of telomerase activity via the telomerase repeat amplification protocol (TRAP) assay. We report here that detection of DNA CCs via qPCR and mRNA quantification of *TERT* are also usable biomarkers that can reliably detect ALT and may be more applicable in a clinical setting as both assays require minute amounts of DNA and RNA. In conclusion, identification of these ALT+ GSCs will enable future explorations of the mechanisms and biology of the ALT phenotype, and will serve as pre-clinical models to test novel chemotherapeutic agents in an effort to improve outcomes in a subset of high-grade gliomas and secondary GBM.
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